Sensitivity of metastatic mucinous tailgut cyst adenocarcinoma to gemcitabine and radiation: a case report
Metastatic mucinous adenocarcinoma arising from a tailgut cyst is an ultra-rare cancer. Literature on the chemosensitivity and radiosensitivity of this cancer is lacking, and treatment is extrapolated from rectal cancer management. We are reporting, for the first time, the case of a patient with metastatic tailgut cyst adenocarcinoma who derived 1.5 years of clinical benefit from treatment with gemcitabine, selected as a result of transcriptomic analysis of her circulating tumor cells using an <i>in vitro</i> assay. The cancer was refractory to regimens extrapolated from rectal cancer management (capecitabine with oxaliplatin, and irinotecan). Pelvic recurrence and osseous metastases were clearly radiosensitive. Tumor molecular profile showed microsatellite stable cancer with <i>KRAS</i> p.G13D and <i>TP53</i> p.C176W mutations.
Authors
- Emmanouil Pappou
- Maliha Nusrat (ORCID: https://orcid.org/0000-0002-0417-0416)
- Elisa de Stanchina (ORCID: https://orcid.org/0000-0002-3873-315X)
- Kenneth H. Yu (ORCID: https://orcid.org/0000-0002-4774-2672)
- Julio García‐Aguilar (ORCID: https://orcid.org/0000-0003-2451-0948)
- Karuna Ganesh (ORCID: https://orcid.org/0000-0002-4948-1082)
- Laura H. Tang (ORCID: https://orcid.org/0000-0001-5735-9354)
- Christopher Crane
- Brian P. McCarthy (ORCID: https://orcid.org/0000-0001-5366-7114)
- Leonard B. Saltz (ORCID: https://orcid.org/0000-0001-8353-4670)
- Meredith Bartelstein (ORCID: https://orcid.org/0000-0001-6506-7765)
- David P. Kelsen (ORCID: https://orcid.org/0000-0001-6139-438X)
- Carla Hajj (ORCID: https://orcid.org/0000-0001-8774-1845)
- Mohammad Ali El Amine
Institutions
- New England Biolabs (United States) (US)
- Memorial Sloan Kettering Cancer Center (US)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-12-18
- DOI
- https://doi.org/10.3389/fonc.2025.1621324
- Primary Topic
- Teratomas and Epidermoid Cysts
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Memorial Sloan-Kettering Cancer Center
- National Cancer Institute